We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

NGeneBio Showcases NGS-Based Oncology/Genetic Diseases Kits and NGenePlex nCoV qRT-PCR Kit Against COVID-19

By LabMedica International staff writers
Posted on 29 Sep 2021
Print article
Image: NGenePlex nCoV qRT-PCR Kit (Photo courtesy of NGeneBio)
Image: NGenePlex nCoV qRT-PCR Kit (Photo courtesy of NGeneBio)

NGeneBio (Seoul, Korea) showcased its next-generation sequencing (NGS)-based oncology/genetic diseases kits and NGenePlex nCoV qRT-PCR kit against COVID-19 at AACC 2021.

Dedicated to achieving better health through laboratory medicine, the American Association for Clinical Chemistry, AACC, brings together more than 50,000 clinical laboratory professionals, physicians, research scientists, and business leaders from around the world focused on clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of breaking laboratory science.

At AACC 2021, NGeneBio showcased its NGS-based oncology/genetic diseases kits (BRCA/HEME/SOLID/ONCO/HLA). NGeneBio’s BRCAaccuTest and BRCAaccuTest PLUS are a reagent kit for producing libraries for analyzing the BRCA1 and BRCA2 genes using the NGS method, which analyzes genomic DNA derived from blood or FFPE tissue. The kit is intended for breast and ovarian cancer patients, HBOC (Hereditary breast and ovarian cancer syndrome) patients, and for family history or the age of breast cancer incidence.

Also on display at the event were NGeneBio’s HEMEaccuTest for molecular genetic test of multiple genes related hematologic malignancy; SOLIDaccuTest to explorer variants associated with solid tumors using a comprehensive method of NGS; HLAaccuTest All which is an in vitro diagnostic medical device for HLA (human leukocyte antigen) typing that can identify high-resolution histocompatibility antigens using NGS; and ONCOaccuPanel, a comprehensive solid tumor oncology NGS test.

In addition, NGeneBio demonstrated its NGeneAnalySys software for analysis of the genetic testing data produced by NGS and helps to report in clinical-grade for oncology test, alongside the EasyHLAanalyzer which provides the HLA typing identifying human leukocyte antigen for histocompatibility antigens using data from NGS. Also on display at AACC 2021 was NGeneBio’s NGenePlex nCoV qRT-PCR Kit which is a reagent of real-time reverse transcription-polymerase chain reaction (RT-PCR) assay intended for the qualitatively detecting nucleic acid of SARS-CoV-2 from patients infected or suspected of COVID-19.

Related Links:
NGeneBio 

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit

Print article
ADLM

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.